Investors need to pay close attention to Catalent (CTLT) stock based on the movements in the options market lately.

Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors including Quadria Capital and Denmark-based pharmaceutical major Novo Nordisk are among those interested in a ...

Increased demand for biologics and biosimilars is driving the demand for dual chamber prefilled syringes.Rockville, MD, Sept.

On Thursday, Catalent Inc (CTLT) stock saw a decline, ending the day at $60.4 which represents a decrease of $-0.32 or -0.53% from the prior close of $60.72. The stock opened at $60.7 and touched a ...

Catalent, Inc. CTLT reported fourth-quarter fiscal 2024 adjusted earnings per share (EPS) of 65 cents, which was ...

Aug 29 (Reuters) - Contract drug manufacturer Catalent (CTLT.N), opens new tab beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and ...

A contract manufacturing drug organization executive said he believes that Novo Nordisk's (NVO) planned purchase of Catalent (NYSE:CTLT) will spur competition. Beau Garrett, CEO of American ...

(Reuters) - Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional ...

Aug 30 (Reuters) - Catalent (CTLT.N), opens new tab said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".